Clinical Trials Logo

Filter by:
NCT ID: NCT06438679 Enrolling by invitation - Dermatomyositis Clinical Trials

3T Therapy in the Treatment of MDA5-positive Dermatomyositis

Start date: March 19, 2024
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to learn if a combination of tacrolimus, tafocitinib and thalidomide (3T therapy) works to treat severe MDA5 positive dermatomyositis in adults. It will also learn about the safety of 3T therapy. The main questions it aims to answer are: Does 3T therapy prolong the overall survival time of MDA5 positive dermatomyositis? What medical problems do participants have when taking 3T therapy? Participants will: Take 3T therapy every day for 12 months Visit the clinic once every 2 weeks for checkups and tests

NCT ID: NCT06438497 Recruiting - Urolithiasis Clinical Trials

The Effect of Different Body Positions and Channel Sheaths on RIRS

Start date: May 23, 2024
Phase: N/A
Study type: Interventional

Retrograde flexible ureteroscopy (RIRS) is currently the first-line treatment for renal stones < 2cm. Lower pole renal stones(LPS) are a difficult problem for urologists. The flexible negative pressure suction ureteral sheath(f-UAS) can facilitate RIRS to flush out the fragments and dust in time, and provide a clear vision and reduce the renal pelvis pressure(RPP) during operation.Standard lithotomy position is the most commonly used position for RIRS. Besides, T-tilt position is also available for RIRS in special cases. Investigators were inspired by this and proposed the lateral position, which is available in cases of LPS.In long-term practice, investigators have found that the change of position and the use of f-UAS can improve stone-free rate(SFR). Investigators aimed to conduct a prospective randomized controlled trial to compare the SFR of different positions and different ureteral sheaths.

NCT ID: NCT06438250 Recruiting - Malignant Neoplasm Clinical Trials

68Ga-FAPI-JH04 PET/CT: Dosimetry and Biodistribution Studies

Start date: March 1, 2024
Phase: Early Phase 1
Study type: Interventional

68Ga-FAPI-JH04 is a novel radiotracer targeting fibroblast activation protein (FAP). In this study, we observed the safety, biodistribution, and radiation dosimetry of 68Ga-JH040182 in patients with different types of cancer.

NCT ID: NCT06438237 Recruiting - Colonoscopy Clinical Trials

Validation of a Prediction Model for Inadequate Bowel Preparation

Start date: May 6, 2024
Phase:
Study type: Observational

We have developed a novel inadequate bowel preparation prediction model based on a systematic review and meta-analysis. The goal of this observational study is to validate the accuracy of this model.

NCT ID: NCT06437964 Not yet recruiting - Cirrhosis, Liver Clinical Trials

Prophylactic Antibiotics in Endoscopic Secondary Prevention of Gastroesophageal Variceal Bleeding

Start date: May 25, 2024
Phase: N/A
Study type: Interventional

Prophylactic antibiotics like third-generation cephalosporin is recommended for acute gastroesophageal variceal bleeding (GVB). Endoscopic sequential therapy is an option in the secondary prevention of acute gastroesophageal variceal bleeding (GVB). However, the value of prophylactic antibiotics in the endoscopic secondary prevention of GVB is still unclear. It's assumed that the procedure of needle puncture under endoscopy will cause iatrogenic variceal bleeding. Besides, the surface of intraluminal varices is nonsterile, and injection of sclerosing agent or tissue adhesive will put patients at a risk of bacteremia. As a result, it's rational to use antibiotics prophylactically in the endoscopic sequential therapy of GVB. While giving antibotics in all patients might cause abuse of antibiotics. In clinical practice now, the prophylactic administration of antibiotics is quite subjective. We observe that quite a lot of cirrhotic patients had no infection after endoscopic secondary prevention for gastroesophageal variceal bleeding, even they have not been administed prophylactic antibiotics. In this non-inferiority trial, we are aimed to evaluate whether no value of prophylactic antibiotics will increase the postoperative infection or not, in the endoscopic secondary prevention of cirrhotic patients with gastroesophageal variceal bleeding.

NCT ID: NCT06437912 Completed - Scar Clinical Trials

Effectiveness of Botulinum Toxin A in Preventing Scar Formation and Initial Exploration of "Optimal Concentration"

Start date: March 23, 2023
Phase: Early Phase 1
Study type: Interventional

Each year, millions of burn, trauma, or surgical patients worldwide suffer from scarring that severely affects their quality of life and social functioning. In order to prevent and treat diseases related to abnormal scar hyperplasia, clinicians and researchers have adopted various methods, such as scar grinding, surgical resection, drug injection in scar tissue, cryotherapy, laser and so on. However, these methods can not effectively inhibit the abnormal proliferation of scars and improve the adverse effects of existing scars on patients. To date, there is no accepted gold standard for the effective treatment and improvement of abnormal scar tissue.

NCT ID: NCT06437886 Enrolling by invitation - Clinical trials for Cardiac Surgery Patients

High-dose Opioid Versus Opioid-sparing Anaesthesia in Cardiac Surgery

Start date: April 22, 2024
Phase: N/A
Study type: Interventional

BACKGROUND In cardiac surgery, high-dose opioids contributes to adverse events associated with poor postoperative outcomes. There is growing evidence that nerve block-based opioid-sparing protocols may reduce perioperative opioid consumption with equally analgesia management and consequently improve patient's postoperative recovery. OBJECTIVE To determine whether opioid-sparing anaesthesia based on pecto-intercostal fascial block and rectus sheath block (PIFB and RSB) could improve early postoperative recovery after cardiac surgery. DESIGN A randomised controlled trial. SETTING A tertiary hospital. PATIENTS Eighty 45-70 years old patients undergoing cardiac surgery were enrolled. Key exclusion criteria included extubation failure within 24 hours postoperatively, contraindication to interventions or drugs and a history of chronic pain or chronic opioid use. INTERVENTIONS Eligible patients were randomised at a 1 : 1 ratio to receive either PIFB and RSB-based opioid-sapring anaesthesia (intervention group) or opioid-based anaesthesia (control group). MAIN OUTCOME MEASURES The primary outcome was the global score of the 15-item Quality of Recovery (QoR-15) questionnaire at 24 h after surgery. Secondary outcomes included recovery-related time, postoperative pain score and rescue analgesia, health-related quality of life, the incidence of postoperative adeverse events and chronic pain.

NCT ID: NCT06437678 Not yet recruiting - Gastric Cancer Clinical Trials

Phase II Study of Liposomal Irinotecan for Advanced Refractory Gastric Cancer

Start date: May 27, 2024
Phase: Phase 2
Study type: Interventional

To evaluate the objective response rate (ORR) and disease control rate (DCR) of liposomal irinotecan monotherapy in the treatment of recurrent/refractory advanced gastric cancer.

NCT ID: NCT06437652 Recruiting - Sjogren's Syndrome Clinical Trials

An AI Algorithm for Lymphocyte Focus Score of Minor Salivary Gland Biopsy Samples for Diagnosing Sjogren's Syndrome

Start date: October 1, 2023
Phase:
Study type: Observational

The aim of this research is to discover an artificial intelligence (AI) algorithm for lymphocyte focus score in whole slide images of labial minor salivary gland (SG) biopsy samples for diagnosing Sjogren's Syndrome, in order to enhance the precision of pathological interpretation of labial minor SG biopsy samples in patients with suspected Sjogren's syndrome and aid clinicians make an accurate diagnose. A remote AI-assisted pathological interpretation platform for lymphocyte focus score in labial SG will be built for the global based on the research results. The research will propose the AI-assisted pathological interpretation of lymphocyte focus score in labial minor SG biopsy samples in the future guidelines for the diagnosis and treatment of Sjogren's syndrome. The research will: 1. Develop and debug the AI algorithm for lymphocyte focus score in whole slide images of labial minor SG biopsy samples for diagnosing Sjogren's Syndrome; 2. Internal test of the AI algorithm; 3. Clinical validation of the AI algorithm with blind method in multiple centers; 4)Built a remote AI-assisted pathological interpretation platform for lymphocyte focus score in labial SG for the global and Explore its clinical application.

NCT ID: NCT06437600 Not yet recruiting - Clinical trials for Stroke, Acute Ischemic

Immediate Angioplasty For Acute Ischemic Stroke With Severe Intracranial Atherosclerotic Stenosis

MAGIC
Start date: October 2024
Phase: N/A
Study type: Interventional

A multicenter, prospective, open-label, blinded endpoint, randomized controlled trial that aims to evaluate the effect of immediate angioplasty (with or without stenting) for acute ischemic stroke (AIS) with severe intracranial atherosclerotic stenosis (ICAS) in improving the 90-day functional outcome.